Increased R&D Investments and Digitization Propel Growth of Diagnostic Solutions in Asia


Innovation, Technology Integration, and New Customer Segments to Drive Growth  

The industry is being disrupted by integration of the multi-disciplinary capabilities in biology, chemistry and computational power that companies can leverage to develop new solutions to diagnose, treat and manage chronic disease conditions, such as cancer, cardiovascular disease and diabetes. There is immense pressure on companies to build competencies in product development, manufacturing and distribution of new technology platforms such as point-of-care molecular diagnostics to capture new growth opportunities in the precision medicine market—a paradigm shift that will transform clinical practice and treatment outcomes.

Expert insight you won't want to miss: 

  • Discover new growth opportunities from innovative technologies and disruptive business models.
  • Assess the profitable customer segments.
  • Strategize global partnerships and digital components (e-commerce).


This site uses cookies. Cookies are used to track visitors to so we can better understand which portions of our site best serve you. This data will be used for the following purposes: Completion and support of the current activity and Web site and system administration. This data will be used only by Frost & Sullivan.